title: The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder.
abstract: OBJECTIVE
  Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.
  
  
  METHODS
  Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.
  
  
  RESULTS
  The point estimate for the incremental cost-effectiveness ratio is -28,068 EUR (-30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.
  
  
  CONCLUSIONS
  TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.
authors.affiliation: a Department of Head and Neck Oncology and Surgery , The Netherlands Cancer Institute , Amsterdam , The Netherlands.
authors.forename: Andreas
authors.initials: A
authors.lastname: Heres Diddens
authors.affiliation: a Department of Head and Neck Oncology and Surgery , The Netherlands Cancer Institute , Amsterdam , The Netherlands.
authors.forename: Sophie
authors.initials: S
authors.lastname: Kraaijenga
authors.affiliation: b Department of Epidemiology and Biostatistics , VU University Medical Center , Amsterdam , The Netherlands.
authors.forename: Veerle
authors.initials: V
authors.lastname: Coupé
authors.affiliation: a Department of Head and Neck Oncology and Surgery , The Netherlands Cancer Institute , Amsterdam , The Netherlands.|c Institute of Phonetic Sciences, University of Amsterdam , Amsterdam , The Netherlands.
authors.forename: Frans
authors.initials: F
authors.lastname: Hilgers
authors.affiliation: a Department of Head and Neck Oncology and Surgery , The Netherlands Cancer Institute , Amsterdam , The Netherlands.
authors.forename: Lisette
authors.initials: L
authors.lastname: van der Molen
authors.affiliation: a Department of Head and Neck Oncology and Surgery , The Netherlands Cancer Institute , Amsterdam , The Netherlands.|d Department of Maxillofacial Surgery , Academic Medical Center , Amsterdam , The Netherlands.
authors.forename: Ludi
authors.initials: L
authors.lastname: Smeele
authors.affiliation: e Department of Psychosocial Research and Epidemiology , The Netherlands Cancer Institute , Amsterdam , The Netherlands.
authors.forename: Valesca
authors.initials: V
authors.lastname: Retèl
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003362:Cost-Benefit Analysis; D005081:Exercise Therapy / Q000191:economics* / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D052580:Muscle Stretching Exercises / Q000191:economics / Q000379:methods; D026741:Physical Therapy Modalities / Q000191:economics; D019057:Quality-Adjusted Life Years; D012680:Sensitivity and Specificity; D013705:Temporomandibular Joint Disorders / Q000209:etiology / Q000628:therapy*; D055815:Young Adult
keywords: Temporomandibular disorder; TheraBite; cost-effectiveness; mandibular function; orofacial pain; physical therapy; quality of life; trismus